TORONTO and HAIFA, Israel, Oct. 05, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, is excited to announce excited to announce that Dr. Lior Shaltiel, CEO of NurExone Biologic, will be presenting advances in exosome-based therapy for spinal cord injury (SCI) and other traumatic central nervous system (CNS) indications. Dr. Shaltiel’s presentation will focus on the transformative potential of extracellular vesicles loaded with PTEN-siRNA (ExoPTEN) and the key challenges in translating this innovative therapy to the clinical stage, following the positive response from the Company’s pre-IND meeting with the U.S. Food and Drug Administration that was announced recently.
During the presentation, Dr. Shaltiel will address critical aspects of NurExone’s ExoTherapy (exosome-based therapy), including the loading efficiency of extracellular vesicles (EVs) with siRNA and the large-scale production of EVs utilizing a revolutionary 3D bioprocess concept. These advancements represent a step forward in the field of recovery from spinal cord injury and hold promise for patients globally.
The presentation will take place at the Extracellular Vesicles Forum in Cambridge, UK, on October 10th and 11th at the session titled “Exosome Based Therapies and Regenerative Medicine.” Dr. Shaltiel will be available for one-on-one meetings during the conference.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and the company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Dr. Eva Reuter
Investment Relation - Germany
This press release contains certain “forward-looking statements”, that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the Company’s ExoTherapy drug, ExoPTEN. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.
In developing the forward-looking statements in this press release, we have applied several material assumptions, including our ability to retain key personnel, our ability to continue investing in research and development, our ability to secure available funding and to continue as a going concern, the general business and economic conditions of the industries and countries in which we operate, our ability to execute on our business strategy, that there will be certain amount of demand for the Company’s potential product, inflation will remain stable, and that the results of our studies reflect results that can be extrapolated.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s early stage of development, lack of revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence on key personnel, protection of the Company’s intellectual property, dependence on the Company’s strategic partners and the risks discussed under the heading “Risk Factors” on pages 29 to 36 of the Company’s Annual Information Form dated March 30, 2023, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.